Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

Pemvidutide

INVESTIGATIONAL

GLP-1 and glucagon receptor dual agonist

11
graded results
0
ongoing records
7
effect domains
Evidence spread
High evidence 0Moderate evidence 2Low evidence 3Very low evidence 6

Pemvidutide is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity and metabolic liver disease; Subcutaneous injection; as of 2026-07-13. Altimmune

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pemvidutide INVESTIGATIONAL
lipids-lipoprotein Decrease
Low evidence

Pemvidutide produced large TG and LDL/total-cholesterol reductions in phase 2 MOMENTUM obesity (glucagon-driven lipid effect).

Altimmune MOMENTUM Phase 2 (ADA 2024, abstract 262-OR) Source
PopulationPhase 2 MOMENTUM; overweight/obesity; pemvidutide 1.2/1.8/2.4 mg vs placebo; 48 weeks.
Fundingindustry - Altimmune (sponsor of record; disclosed)
Comparatorsplacebo
Pemvidutide INVESTIGATIONAL
lipids-lipoprotein Decrease
Very low evidence

Robust reductions in serum lipids

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationMOMENTUM obesity phase 2 (n=391), 48 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pemvidutide INVESTIGATIONAL
body-composition Decrease
Very low evidence

MOMENTUM phase 2 MRI-based body-composition substudy: pemvidutide reported ~78.1% of weight lost as fat and ~21.9% as lean mass, framed by the sponsor as...

Altimmune, MOMENTUM phase 2 MRI body-composition substudy, ADA 2024 / EASD 2024 Source
Full findingMOMENTUM phase 2 MRI-based body-composition substudy: pemvidutide reported ~78.1% of weight lost as fat and ~21.9% as lean mass, framed by the sponsor as 'class-leading' lean-mass preservation.
PopulationMOMENTUM 48-week phase 2 obesity trial; MRI body-composition substudy n=50 pemvidutide; presented ADA 2024 / EASD 2024
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Pemvidutide INVESTIGATIONAL
body-composition Mixed
Very low evidence

High lean-mass preservation in MRI body-composition substudy

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationMOMENTUM MRI substudy (n=50), 48 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pemvidutide INVESTIGATIONAL
weight-loss Decrease
Moderate evidence

In a 24-week MASLD trial, pemvidutide produced ~6% weight loss as a secondary outcome.

Pemvidutide in MASLD, 24-week, J Hepatol Rep 2025 Source
PopulationPeer-reviewed RCT / meta-analysis
FundingAltimmune
Pemvidutide INVESTIGATIONAL
weight-loss Decrease
Very low evidence

Dose-dependent weight loss over 48 wk in obesity/overweight without diabetes (MOMENTUM)

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationObese/overweight + ≥1 comorbidity, no diabetes (n=391), phase 2 MOMENTUM, 48 wk, RCT 1:1:1:1
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pemvidutide INVESTIGATIONAL
Liver and MASH Mixed
Moderate evidence

In IMPACT (phase 2b, F2-F3), the GLP-1/glucagon dual pemvidutide MET one dual-primary (MASH resolution) but DID NOT MEET the other (fibrosis improvement) at 24 weeks;...

Noureddin M, Harrison SA, Loomba R et al. Pemvidutide vs placebo for MASH (IMPACT): 24-we... Source
Full findingIn IMPACT (phase 2b, F2-F3), the GLP-1/glucagon dual pemvidutide MET one dual-primary (MASH resolution) but DID NOT MEET the other (fibrosis improvement) at 24 weeks; the fibrosis differences vs placebo were small and non-significant (p=0.59 and p=0.27). Reported honestly: fibrosis was a MISS at 24 weeks.
PopulationNCT05989711 (IMPACT); 212 randomised (1:2:2 placebo:1.2:1.8 mg); biopsy MASH fibrosis F2/F3; phase-2b randomised double-blind placebo-controlled trial; 24-week readout of a 48-week trial.
Fundingindustry - Altimmune, Inc.
Comparatorsplacebo
Pemvidutide INVESTIGATIONAL
Liver and MASH Decrease
Low evidence

Reduced liver fat content, ALT and cT1 vs placebo in MASLD

Harrison SA et al. J Hepatol 2024;82:7-17 Source
PopulationBMI ≥28, LFC ≥10% MASLD (n=94), phase 1b/2a, 12 wk, RCT placebo-controlled (NCT05006885)
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pemvidutide INVESTIGATIONAL
blood-pressure Decrease
Very low evidence

Improvements in blood pressure without meaningful heart-rate increase or cardiac/arrhythmia imbalance

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationMOMENTUM obesity phase 2 (n=391), 48 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pemvidutide INVESTIGATIONAL
Heart rate No change
Very low evidence

No clinically meaningful heart-rate increase reported

Altimmune MOMENTUM topline / ADA 2024 Source
PopulationMOMENTUM obesity phase 2 (n=391), 48 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Pemvidutide INVESTIGATIONAL
Stomach and gut Increase
Low evidence

Well tolerated in MASLD study with no severe/serious AEs

Harrison SA et al. J Hepatol 2024;82:7-17 Source
PopulationMASLD phase 1b/2a (n=94), 12 wk
Fundingindustry - Altimmune (trial sponsor; inferred from registration trial)
Comparatorsplacebo